Eledon Pharmaceuticals (ELDN) Stock Price, News & Analysis

Company Overview

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Key Stats

• Today's Range: $3.06 to $3.16
• 50-Day Range: $2.60 to $3.31
• 52-Week Range: $2.30 to $5.54
• Volume: 194,685 shs
• Average Volume: 314,444 shs
• Market Capitalization: $179.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Buy

Eledon Pharmaceuticals Stock Analysis - MarketRank™

Eledon Pharmaceuticals scored higher than 40% of companies evaluated by MarketBeat, and ranked 656th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Eledon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Eledon Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Eledon Pharmaceuticals are expected to decrease in the coming year, from ($0.81) to ($1.01) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Eledon Pharmaceuticals is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Eledon Pharmaceuticals is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Eledon Pharmaceuticals has a P/B Ratio of 1.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.53% of the float of Eledon Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Eledon Pharmaceuticals has a short interest ratio ("days to cover") of 6.1.

Change versus previous month

Short interest in Eledon Pharmaceuticals has recently decreased by 8.90%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Eledon Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Eledon Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.53% of the float of Eledon Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Eledon Pharmaceuticals has a short interest ratio ("days to cover") of 6.1.

Change versus previous month

Short interest in Eledon Pharmaceuticals has recently decreased by 8.90%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Eledon Pharmaceuticals this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Eledon Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.30% of the stock of Eledon Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

56.77% of the stock of Eledon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ELDN Stock Analysis - Frequently Asked Questions

How have ELDN shares performed this year?

Eledon Pharmaceuticals' stock was trading at $4.12 at the beginning of the year. Since then, ELDN shares have decreased by 27.1% and is now trading at $3.0050.

How were Eledon Pharmaceuticals' earnings last quarter?

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) issued its earnings results on Wednesday, May, 14th. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.28) by $0.20.

Who are Eledon Pharmaceuticals' major shareholders?

Top institutional shareholders of Eledon Pharmaceuticals include Howard Financial Services LTD. (0.05%).
View institutional ownership trends.

How do I buy shares of Eledon Pharmaceuticals?

Shares of ELDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Eledon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eledon Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/05/2025
• Next Earnings (Estimated): 8/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ELDN
• CIK: 1404281
• Web: novustherapeutics.com
• Phone: (949) 238-8090
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $9.00
• High Stock Price Target: $9.00
• Low Stock Price Target: $9.00
• Potential Upside/Downside: +199.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$36.18 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -79.54%
• Return on Assets: -41.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.90
• Quick Ratio: 13.91

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.98 per share
• Price / Book: 1.52

Miscellaneous

• Outstanding Shares: 59,880,000
• Free Float: 52,517,000
• Market Cap: $179.94 million
• Optionable: Optionable
• Beta: -0.16